公开(公告)号：US12227509B2

公开(公告)日：2025-02-18

申请号：US17422108

申请日：2020-01-10

Applicant: Shionogi & Co., Ltd.

Inventor： Yusuke Tateno ,  Manabu Katou ,  Toshihiro Wada

IPC: C07D487/10 ,  A61P3/04 ,  C07D491/20

Abstract: The present invention provides a compound represented by a following formula. A compound represented by, wherein R1 is hydrogen, hydroxy, or the like; R2a and R2b may be taken together with an adjacent carbon atom to form ring B, ring B is a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle; R3a is hydrogen, halogen, hydroxy, or the like; R3b is hydrogen, halogen, hydroxy, or the like; R4a is a group represented by formula: L3 is a single bond or substituted or unsubstituted alkylene, R7 is hydrogen, halogen, hydroxy, or the like, and R4b is halogen, cyano, carboxy, or the like, or its pharmaceutically acceptable salt.

公开(公告)号：US12187742B2

公开(公告)日：2025-01-07

申请号：US17074425

申请日：2020-10-19

Applicant: XRAD Therapeutics, Inc.

Inventor： Jianmin Fu ,  Yaode Wang ,  Yue Sun ,  Guosheng Wu ,  Aijun Lu ,  Shuang Zhang ,  Robert Goodnow ,  Tona Gilmer ,  Michael Kastan ,  David Kirsch

IPC: C07D519/00 ,  C07D471/04 ,  C07D491/20

Abstract: Provided herein are compounds of the Formula (I), (II), and (III): as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.

公开(公告)号：US12171144B2

公开(公告)日：2024-12-17

申请号：US18474865

申请日：2023-09-26

Applicant: LG DISPLAY CO., LTD ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Kyung-Jin Yoon ,  Dae-Wi Yoon ,  Ji-Ae Lee ,  Su-Na Choi ,  Dong-Hoon Choi ,  Min-Ju Cho ,  JiWon Yoon

IPC: H10K85/60 ,  C07D491/20 ,  C07D495/20 ,  C09K11/06 ,  H10K50/11

Abstract: The present disclosure relates to an organic compound having the following structure, and an organic light emitting diode (OLED) and an organic light emitting device including the organic compound. The organic compound can be a bipolar compound having a p-type moiety and an n-type moiety and has high energy level and proper energy bandgap for an emissive layer of the OLED. As the organic compound is applied into the emissive layer, the OLED can maximize its luminous properties as holes and electrons are recombined uniformly over the whole area in an emitting material layer (EML).

公开(公告)号：US12137611B2

公开(公告)日：2024-11-05

申请号：US16702269

申请日：2019-12-03

Applicant: LG Display Co., Ltd. ,  DONGJIN SEMICHEM CO., LTD.

Inventor： Kyung-Jin Yoon ,  Yu-Jin Bae ,  Bo-Min Seo ,  Jeong-Eun Baek ,  Joong-Hwan Yang ,  Chun-Ki Kim ,  Jung-Hyun Yoon ,  Hyung-Won Cho ,  Kyu-Soon Shin ,  Jeong-A Seo ,  Hyung-Jin Lee ,  Young-Sam Jin ,  Dong-Hyun Lee

IPC: H01L51/50 ,  C07D491/20 ,  C07D519/00 ,  C09K11/06 ,  H10K85/60 ,  H10K50/11 ,  H10K50/13 ,  H10K50/15 ,  H10K50/16 ,  H10K50/17 ,  H10K50/844 ,  H10K101/10 ,  H10K101/30 ,  H10K101/40

Abstract: The present disclosure provides a compound of following formula and an organic light emitting device and an organic light emitting display device including the compound. The compound of the present disclosure serves as a host or a dopant in an emitting material layer.

公开(公告)号：US20240246910A1

公开(公告)日：2024-07-25

申请号：US18405058

申请日：2024-01-05

Applicant: Sensorium Therapeutics, Inc.

Inventor： Jacob M. Hooker ,  Michael S. Placzek

IPC: C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/18

CPC classification number: C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/1804

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

公开(公告)号：US20240239805A1

公开(公告)日：2024-07-18

申请号：US18541565

申请日：2023-12-15

Applicant: University of Kansas

Inventor： Manvendra Pal Singh ,  Zarko Boskovic ,  Bryce Gaskins

IPC: C07D491/20 ,  C07D471/04

CPC classification number: C07D491/20 ,  C07D471/04

Abstract: The present disclosure is directed to a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V




or a pharmaceutically acceptable salt and/or solvate thereof.

公开(公告)号：US11964986B1

公开(公告)日：2024-04-23

申请号：US18217914

申请日：2023-07-03

Applicant: REJUVERON TELOMERE THERAPEUTICS AG

Inventor： Patrick Schnider ,  Fedor Romanov Michailidis ,  Chien-Chi Hsiao

IPC: C07D491/20 ,  C07D491/147

CPC classification number: C07D491/147

Abstract: The present invention relates to 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives, their manufacture, pharmaceutical compositions containing them and their use as a medicament.

公开(公告)号：US20240124443A1

公开(公告)日：2024-04-18

申请号：US18264310

申请日：2022-01-28

Applicant: SCINNOHUB PHARMACEUTICAL CO., LTD

Inventor： Anle YANG ,  Sen JI ,  Zhi WANG ,  Hao WANG ,  Dewei ZHANG ,  Xiao WANG ,  Huan SHEN ,  Jie XIANG ,  Jialing XIAN ,  Yan WANG ,  Xiao HU ,  Xiaodong ZHANG ,  Jun TANG

IPC: C07D471/04 ,  A61P7/04 ,  C07D491/20

CPC classification number: C07D471/04 ,  A61P7/04 ,  C07D491/20

Abstract: The present invention relates to a compound of formula (I) capable of inhibiting plasmin activity and having blood coagulation and hemostasis activity, and a pharmaceutically acceptable salt, hydrate, isomer, prodrug and mixture thereof, wherein R1 to R3 are as defined in the description.

公开(公告)号：US11939335B2

公开(公告)日：2024-03-26

申请号：US18199900

申请日：2023-05-19

Applicant: 858 Therapeutics, Inc.

Inventor： James M. Veal ,  Jeffrey A. Stafford ,  Donald S. Karanewsky ,  Shyama Herath

IPC: A61K31/519 ,  C07D487/04 ,  C07D487/14 ,  C07D491/147 ,  C07D491/20 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D491/147 ,  C07D491/20 ,  C07D519/00 ,  C07B2200/05

Abstract: Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease. Said inhibitors of PARG have the structure provided in Formula (I):




as represented, for example, by Example 1:

公开(公告)号：US20230374022A1

公开(公告)日：2023-11-23

申请号：US18199900

申请日：2023-05-19

Applicant: 858 Therapeutics, Inc.

Inventor： James M. VEAL ,  Jeffrey A. STAFFORD ,  Donald S. KARANEWSKY ,  Shyama HERATH

IPC: C07D487/04 ,  C07D491/147 ,  C07D491/20 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D491/147 ,  C07D491/20 ,  C07D519/00 ,  C07B2200/05

Abstract: Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.